New gout combo drug enters early human testing

NCT ID NCT07367971

Recruiting now Disease control Sponsor: Atom Therapeutics Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing whether a new investigational drug called ABP-671 can be safely taken together with the standard gout medication allopurinol. Twenty adults with gout who are already on a stable dose of allopurinol will take the drugs alone and together over three weeks. The main goal is to measure how the two drugs interact in the body, not yet to see if ABP-671 improves gout symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABP-671 (an investigational drug) and allopurinol (a standard gout medication)
What this could lead to: If successful, this study could show that ABP-671 can be safely added to allopurinol therapy, potentially offering a new combination option for controlling gout.
What could go wrong: This is a very early Phase 1 study with only 20 participants. It is designed to check drug interactions, not to prove that ABP-671 works for gout. The results may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DDI (DRUG-DRUG INTERACTION) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DDI (DRUG-DRUG INTERACTION) GOUT GOUT CHRONIC

Contacts and locations

Locations

Wakefield Clinical Research
RECRUITING

Cary, North Carolina, 27560, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.